Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen Idec 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec

3Q Revenues: $789 million (+12%)

3Q Earnings: $119 million (-24%)

YTD Revenues: $2.3 billion (+15%)

YTD Earnings: $437 million (+301%)

Comments: Avonex sales leveled off, up 2% to $455 million, while BI’s share of Rituxan revenues rose 15% to $235 million. During the quarter, the company’s named Paul Clancy to the role of chief financial officer. Two months later, BI’s board authorized management to look for a buyer for the company.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters